GSK opts into Ionis' HBV program  Positive Phase II data prompted GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to exercise its option to license exclusive, worldwide rights to an antisense chronic HBV program from Ionis Pharmaceuticals Inc. (NASDAQ:IONS)....

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million on Sept. 20 in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and...

Tvardi Therapeutics Inc. (Houston, Texas) raised $9 million in a series A round from Alexandria Venture Investments and other undisclosed institutional and private investors. Tvardi is developing inhibitors of signal transducer and activator of transcription...

Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas   Business: Cancer   Date completed: 2015-10-01   Type: IPO   Raised: $43.8 million   Shares: 6.3 million   Price: $7   Shares after offering: 20.1 million   Underwriters:...

Mirna Therapeutics Inc. (NASDAQ:MIRN), Austin, Texas   Business: Cancer   Date completed: 2015-10-01   Type: Private placement   Raised: $16.8 million   Shares: 2.4 million   Price: $7   Shares after offering: 20.1 million  ...

immatics and MD Anderson launched standalone company Immatics US Inc. (Houston, Texas) to develop autologous and allogeneic adoptive cellular therapies to treat tumors. The newco has access to MD Anderson’s expertise and immatics’ “cancer target...

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date announced: 2015-09-18   Type: IPO   To be raised: Up to $69.8 million   Shares: 4.7 million   Price: $13-$15   Underwriters: Citigroup; Leerink Partners;...

Mirna Therapeutics Inc. , Austin, Texas   Business: Cancer   Date announced: 2015-09-11   Type: IPO   To be raised: Up to $80.5 million   Shares: TBD   Price: TBD   Underwriters: Citigroup; Leerink Partners; Oppenheimer;...

BioCentury's annual analysis of public-private partnerships and early stage venture financing activity shows that the model of using PPPs to foster academic innovation is holding fast, and that academia is an active driver behind the...

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....